Soligenix, Inc. a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases announced that it has appointed Daniel P. Ring as Vice President of Business Development and Strategic Planning, effective immediately.
Ring has over 22 years of business development and commercial experience in the biopharmaceutical industry. In this new role, he will oversee the Company’s global business development function, which will include balanced and disciplined management of any current or new strategic business opportunities, initiatives, mergers, acquisitions, partnerships, alliances, and/or licensing agreements.
“We are excited to have a seasoned industry veteran like Dan join our team,” stated Christopher J. Schaber, Ph.D., president and CEO of Soligenix. “Dan’s business development and commercial experience, as well as his strategic vision, will be invaluable as we continue to evaluate the multiple opportunities before us, including advancing our Phase 3 clinical programs towards commercialization.”
Previously, Ring served as the vice president of Business Development at Exela Pharma Sciences, LLC, where he was responsible for creating the company’s U.S. commercial operations and growing its revenue and income via transactions with strategic partners. Previously, he was an executive with Merck & Co., Inc. for 17 years, in various sales, marketing and finance positions, rising to Executive Director of Corporate Licensing. He received his BA from Villanova University and an MBA, with a concentration in accounting, from the Thunderbird School of Global Management at Arizona State University.